Clinical data for NSCLC remain scarce, but pyrotinib has higher antitumor activity than afatinib in HER2-mutant organoid systems82, and a phase II trial enrolling chemotherapy-pretreated patients with HER2-mutant advanced lung adenocarcinoma has indicated promising activity, with a PFS of 6.9 months83. Here, ERBB2 is linked to non-small cell lung carcinoma.